Page last updated: 2024-11-02

oxybutynin and Nasopharyngitis

oxybutynin has been researched along with Nasopharyngitis in 1 studies

oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.

Nasopharyngitis: Inflammation of the NASOPHARYNX, usually including its mucosa, related lymphoid structure, and glands.

Research Excerpts

Excerpt	Relevance	Reference
" Primary safety outcomes included occurrence of adverse events and dropouts."	2.76	Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. ( Beneš, H; Ferini-Strambi, L; Fichtner, A; García-Borreguero, D; Högl, B; Kohnen, R; Oertel, W; Poewe, W; Schollmayer, E; Stiasny-Kolster, K; Trenkwalder, C, 2011)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Oertel, W	1
Trenkwalder, C	1
Beneš, H	1
Ferini-Strambi, L	1
Högl, B	1
Poewe, W	1
Stiasny-Kolster, K	1
Fichtner, A	1
Schollmayer, E	1
Kohnen, R	1
García-Borreguero, D	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
An Open-label Extension Trial to Determine Safety and Tolerability of Long-term Transdermal Application of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome[NCT00498186]			Phase 2	295 participants (Actual)	Interventional	2003-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Subjects Who Withdrew From the Trial Due to an Adverse Event During the 5-year Open Label Extension

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment. (NCT00498186)
Timeframe: Up to five years

Intervention	participants (Number)
Rotigotine	93

Number of Subjects With at Least One Adverse Event, as Reported Spontaneously by the Subject or Observed by the Investigator, During the 5-year Open-label Extension.

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment. (NCT00498186)
Timeframe: Up to five years

Intervention	participants (Number)
Rotigotine	273

Trials

1 trial available for oxybutynin and Nasopharyngitis

Article	Year
Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. The Lancet. Neurology, 2011, Volume: 10, Issue:8 Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Double-Blind Method; Female; Follow-Up Studies;	2011